# Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration

> **NCT00764738** · PHASE2,PHASE3 · COMPLETED · sponsor: **Retina Macula Institute** · enrollment: 91 (actual)

## Conditions studied

- Neovascular Age Related Macular Degeneration

## Interventions

- **DEVICE:** OCT, Multifocal ERG, Microperimetry
- **DRUG:** Ranibizumab Ophthalmic

## Key facts

- **NCT ID:** NCT00764738
- **Lead sponsor:** Retina Macula Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2020-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00764738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00764738, "Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00764738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*